SCHEMBL21724972

SCHEMBL21724972

Nc1cc(-c2ccnn2C2CCCCO2)ccc1B(O)O

nearest known ligand 0.50

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
CYP4F2 P78329 4/20 0.50
CYP4A11 Q02928 4/20 0.50
ATR Q13535 14/20 0.43
IDH1 O75874 1/20 0.42
NR3C2 P08235 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18985877 0.86 CYP4F2 (0.50) CYP4F2CYP4A11ATRIDH1NR3C2
SCHEMBL20641888 0.83 CYP4F2 (0.46) CYP4F2CYP4A11ATRIDH1
SCHEMBL21729100 0.82 CYP4F2 (0.47) CYP4F2CYP4A11ATRIDH1
SCHEMBL23154226 0.79 ATR (0.49) CYP4F2CYP4A11ATRIDH1
SCHEMBL1817328 0.76 ATR (0.50) CYP4F2CYP4A11ATRIDH1
SCHEMBL12079810 0.76 CYP4F2 (0.50) CYP4F2CYP4A11ATRIDH1
SCHEMBL2685154 0.76 CYP4F2 (0.51) CYP4F2CYP4A11ATR
SCHEMBL22008923 0.74 CYP4F2 (0.54) CYP4F2CYP4A11ATRIDH1
SCHEMBL20651806 0.74 CYP4F2 (0.49) CYP4F2CYP4A11ATRIDH1
SCHEMBL22234134 0.74 CYP4F2 (0.44) CYP4F2CYP4A11ATRIDH1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11827597-B2 Substituted 4-amino-1H-imidazo[4,5-c]quinoline compounds and improved methods for their preparation INNATE TUMOR IMMUNITY, INC. (US) 2023-11-28 US disclosed
US-11827597-B2 Substituted 4-amino-1H-imidazo[4,5-c]quinoline compounds and improved methods for their preparation INNATE TUMOR IMMUNITY, INC. (US) 2023-11-28 US disclosed
US-20230097144-A1 SUBSTITUTED 4-AMINO-1H-IMIDAZO[4,5-c]QUINOLINE COMPOUNDS AND IMPROVED METHODS FOR THEIR PREPARATION INNATE TUMOR IMMUNITY INC (US) 2023-03-30 US disclosed
US-11572360-B2 Substituted 4-amino-1H-imidazo[4,5-c]quinoline compounds and improved methods for their preparation INNATE TUMOR IMMUNITY, INC. (US) 2023-02-07 US disclosed
US-20210332040-A1 SUBSTITUTED 4-AMINO-1H-IMIDAZO[4,5-c]QUINOLINE COMPOUNDS AND IMPROVED METHODS FOR THEIR PREPARATION INNATE TUMOR IMMUNITY INC (US) 2021-10-28 US disclosed
EP-3837245-A1 SUBSTITUED 4-AMINO-1H-IMIDAZO[4,5-C]QUINOLINE COMPOUNDS AND IMPROVED METHODS FOR THEIR PREPARATION Innate Tumor Immunity, Inc. (US) 2021-06-23 EP disclosed
WO-2020037094-A1 SUBSTITUED 4-AMINO-1H-IMIDAZO[4,5-C]QUINOLINE COMPOUNDS AND IMPROVED METHODS FOR THEIR PREPARATION INNATE TUMOR IMMUNITY, INC. (US) 2020-02-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230097144-A1 SUBSTITUTED 4-AMINO-1H-IMIDAZO[4,5-c]QUINOLINE COMPOUNDS AND IMPROVED METHODS FOR THEIR PREPARATION NLRP3, NOD1, NLRP1 CYP4F2 1429/4885CYP4A11 338/4885ATR 2353/4885
US-11827597-B2 Substituted 4-amino-1H-imidazo[4,5-c]quinoline compounds and improved methods for their preparation NLRP3, NOD1, NLRP1 CYP4F2 1429/4885CYP4A11 338/4885ATR 2353/4885
US-11572360-B2 Substituted 4-amino-1H-imidazo[4,5-c]quinoline compounds and improved methods for their preparation NLRP3, NOD1, NLRP1 CYP4F2 1429/4885CYP4A11 338/4885ATR 2353/4885
US-20210332040-A1 SUBSTITUTED 4-AMINO-1H-IMIDAZO[4,5-c]QUINOLINE COMPOUNDS AND IMPROVED METHODS FOR THEIR PREPARATION NLRP3, NOD1, NLRP1 CYP4F2 1429/4885CYP4A11 338/4885ATR 2353/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.